Overview

A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of adalimumab in Japanese subjects with moderately to severely active ulcerative colitis (UC).
Phase:
Phase 3
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Collaborator:
Eisai Co., Ltd.
Treatments:
Adalimumab